NCT03822650

A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

A Natural History and Outcome Measure Discovery Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 37 (actual)
• Sponsor: Neurogene Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

CLN5 is a form of Batten Disease, a neurodegenerative disorder in children causing psychomotor regression, seizures, blindness, loss of ambulation and premature death, and has no available treatments. The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with CLN5. This natural history study is important to better understand disease course to be able to determine clinically relevant outcome measures for use in future clinical trials.

Detailed description

Neuronal Ceroid Lipofuscinosis (NCL) are comprised of a group of fatal neurodegenerative diseases caused by mutations in an enzyme or protein which results in the accumulation of toxic deposits in the eye, brain, skin, muscle and other cells. CLN5 is a type of NCL, caused by homozygous or bi-allelic heterozygous variants in the CLN5 gene. Lack of CLN5 protein impairs the breakdown of certain proteins, leads to defective lysosomal trafficking, resulting in accumulation of toxic material and subsequent cell damage. CLN5 disease presents in childhood with neurological findings including motor clumsiness and attention disturbances, followed by progressive visual failure, psychomotor depression, epilepsy, and premature death. No investigational product will be provided in the study.

Conditions

• Ceroid Lipofuscinosis, Neuronal 5

Timeline

• Start date: 2019-03-13
• Primary completion: 2024-05-30
• Completion: 2024-05-30
• First posted: 2019-01-30
• Last updated: 2024-06-27

Locations

1 site across 1 country: United States